You are here

lung cancer

Takeda earns win for its TKI inhibitor in tiny lung cancer group — but GI side effects could be an early red flag

Takeda earns win for its TKI inhibitor in tiny lung cancer group — but GI side effects could be an early red flag

Endpoints

non-small cell lung cancer

Flag link:

Closely Watched Mirati Reveals Results to Rival Amgen Drug

Closely Watched Mirati Reveals Results to Rival Amgen Drug

Bloomberg

Mirati Therapeutics

Flag link:

Flame Biosciences to Ignite Pipeline with $100M Common Stock Financing

Flame Biosciences to Ignite Pipeline with $100M Common Stock Financing

BioSpace

Flame Biosciences

Flag link:

BridgeBio's Navire preps SHP2 blocker for lung cancer trial after positive mouse study

BridgeBio's Navire preps SHP2 blocker for lung cancer trial after positive mouse study

Fierce Biotech

clinical trials

Flag link:

FDA starts quick review of Merck KGaA’s MET-targeting lung cancer drug

FDA starts quick review of Merck KGaA’s MET-targeting lung cancer drug

Pharmaforum

Flag link:

Teva Pharmaceuticals Unit Actavis Generics Wins FDA Approval for Lung Cancer Drug Pemetrexed

Teva Pharmaceuticals Unit Actavis Generics Wins FDA Approval for Lung Cancer Drug Pemetrexed

Motley Fool

Teva Pharmaceutical

Flag link:

AZ aims to cut cancer clinic visits with new Imfinzi regimen

AZ aims to cut cancer clinic visits with new Imfinzi regimen

Pharmaforum

Flag link:

Deaths from the most common lung cancer are falling fast, hinting at the impact of improved treatment

Deaths from the most common lung cancer are falling fast, hinting at the impact of improved treatment

Stat

non-small cell lung cancer

targeted therapeutics

Flag link:

Bristol Myers' Opdivo-Yervoy duo slashes mesothelioma death risk by 26%

Bristol Myers' Opdivo-Yervoy duo slashes mesothelioma death risk by 26%

Fierce Pharma

Bristol-Myers Squibb

clinical trials

Flag link:

Pfizer's Lorbrena makes play for earlier lung cancer use with Xalkori-topping data

Pfizer's Lorbrena makes play for earlier lung cancer use with Xalkori-topping data

Fierce Pharma

clinical trials

Flag link:

A turn-up for Spectrum’s book

A turn-up for Spectrum’s book

EP Vantage

Spectrum Pharmaceuticals

Flag link:

Lung cancer study IDs new 'epigenomic' target for diagnosis and treatment

Lung cancer study IDs new 'epigenomic' target for diagnosis and treatment

Fierce Biotech

Flag link:

In pilot of patient-reported outcomes project, FDA hopes to encourage ‘more rigorous’ data collection

In pilot of patient-reported outcomes project, FDA hopes to encourage ‘more rigorous’ data collection

MedCity News

clinical trials

Flag link:

ASCO data back AZ/Daiichi Sankyo’s Enhertu in new HER2 cancers

ASCO data back AZ/Daiichi Sankyo’s Enhertu in new HER2 cancers

Pharmaforum

colorectal cancer

Flag link:

AstraZeneca's Blockbuster Lung Cancer Drug Has a Huge Sales Boost Ahead

AstraZeneca's Blockbuster Lung Cancer Drug Has a Huge Sales Boost Ahead

Motley Fool

Flag link:

AstraZeneca bid to expand lung cancer drug's use boosted by trial data

AstraZeneca bid to expand lung cancer drug's use boosted by trial data

BioPharma Dive

clinical trials

Flag link:

3 Roche Companies Hope to Make Clinical Trials More Efficient

3 Roche Companies Hope to Make Clinical Trials More Efficient

Medical Devices and Diagnostics Industry

Flatiron Health

Foundation Medicine

clinical trials

Flag link:

AstraZeneca to unveil key data for cancer drugs at ASCO

AstraZeneca to unveil key data for cancer drugs at ASCO

Pharmaforum

colorectal cancer

Flag link:

ASCO 2020 – first-line lung cancer focus

ASCO 2020 – first-line lung cancer focus

EP Vantage

Bristol-Myers Squibb

Flag link:

Go or no go? Oncology dominates upcoming decisions

Go or no go? Oncology dominates upcoming decisions

EP Vantage

prostate cancer

Bristol-Myers Squibb

Flag link:

Pages